HL-7 and HL-10 Peptides Stimulate Insulin Secretion in the INS-1 Insulinoma Cell Line through Incretin-Dependent Pathway and Increasing the Glucose Uptake in L6 Myoblast

被引:0
作者
Zahra Setayesh-Mehr
Mahdiye Poorsargol
机构
[1] University of Zabol,Department of Biology, Faculty of Sciences
[2] University of Zabol,Department of Chemistry, Faculty of Sciences
来源
International Journal of Peptide Research and Therapeutics | 2021年 / 27卷
关键词
Peptide; Insulin secretion; Dipeptidyl peptidase-4; Glucose uptake; HL-7; HL-10;
D O I
暂无
中图分类号
学科分类号
摘要
In this study, the effect of two peptides, namely HL-7 and HL-10, on the percentage of cell death in L6 myoblast, proliferation, and metabolism of glucose in the INS-1 cell line, and the inhibitory role in the dipeptidyl peptidase IV (DPPIV) enzyme was investigated. The MTT assay was carried out to measure cell death and glucose metabolism in L6 myoblast and INS-1 cells, respectively. The analyses of glucose uptake in L6 myoblast and proliferation of INS-1 cells were performed in a culture medium containing 8 mM glucose and by the MTT kit, respectively. The inhibitory activity of two peptides against DPPIV was also conducted in-vitro and in-silico. Moreover, molecular docking and molecular dynamics simulations were done to estimate the stability and ability of HL-7 and HL-10 ligands in complex with the target enzyme. The results showed that both peptides had almost the same effects as the positive controls used in the two experiments on glucose uptake and cell proliferation (insulin and GABA, respectively). The glucose metabolism analysis showed an increase in insulin secretion in INS-1 cells treated with two peptides in a dose-dependent manner. The inhibitory assay experiments demonstrated that the IC50 values of peptides HL-7 and HL-10 for DPPIV were 17.04 and 18.75 µM, respectively. Also, in-vitro and in-silico results indicated the competitive behavior of the two peptides against the activity of DPPIV. Overall, it seems that the two peptides, HL-7, and HL-10 are able to increase insulin secretion by increasing the proliferation and of pancreatic beta cells and incretin-dependent pathways, such as the inhibition of the DPPIV enzyme.
引用
收藏
页码:2231 / 2244
页数:13
相关论文
共 220 条
  • [11] Tauriello G(2009)Block of K v 1.7 potassium currents increases glucose-stimulated insulin secretion Drug Metab Dispos Biol Fate Chem 37 1164-1171
  • [12] Studer G(2012)Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections Toxicon 59 464-471
  • [13] Bordoli L(2011)The development of Byetta (exenatide) from the venom of the Diabetes Obes Metab 13 348-356
  • [14] Schwede T(2016) as an anti-diabetic agent Pharmacol Rev 68 954-1013
  • [15] Cnop MN(2005)Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes Theory Appl Comput Chem 13 251-262
  • [16] Welsh JC(2012)Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes Nat Rev Mol Cell Biol 92 193-200
  • [17] Jonas A(2014)Advances in electronic structure theory: GAMESS a decade later Toxicon 4 435-447
  • [18] Jorns S(2008)AMPK: a nutrient and energy sensor that maintains energy homeostasis J Chem Theory Comput 9 151-155
  • [19] Lenzen DL(2018)Toxins and drug discovery Ther Adv Endocrinol Metab 35 482-485
  • [20] Eizirik E(1992)GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation Diabetol Clin Exp Diabetes Metab 281 5522-5531